§ Mr. BurstowTo ask the Secretary of State for Health if the improvements in the purity of Pyridostigmine Bromide have resulted in improved resolutions in the medical treatment of myasthenia gravis. [40109]
§ Ms JowellPyridostigmine bromide is a well established treatment for the management of myasthenia gravis. The European Pharmacopoeia specification has recently changed (with effect from 1 January 1998) and tighter and more detailed limits for impurities have been set. However, there is no reason to suppose that this would result in any improvement in the treatment of myasthenia gravis and the Medicines Control Agency has received no evidence on the effect of these improvements in the purity of pyridostigmine bromide.